Study S003300

A Randomized, Double-blind, Placebo-controlled, Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous (SC) Doses of HDM1005 Injection in Overweight or Obese Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06637020
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 80
Start: 2024-06-21
Primary completion: 2025-03-28
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Overweight and Obesity
Interventions: DRUG:HDM1005 injection or placebo
Results posted: FALSE

Registered primary outcomes

The incidence, severity, and causality of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) [Signing informed until day 57]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0050051	142-OR: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study YIJUN DU, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06637020